Clinical Evaluation and Future Prospects of Asparaginase

  • J. H. Burchenal
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 30)


The original discovery of the antileukemic effects of guinea pig serum by Kidd [1] in 1953 and the subsequent biological and chemical studies on its active principle, L-asparaginase (A-ase), by many investigators including Broome [2], Mashburn and Wriston [3], and Old, Boyse et al. [4, 5] are well known. Following the preliminary clinical studies on A-ase reported by De Barros et al. [6], Dolowy et al. [7], Hill et al. [8], and Oettgen et al. [9], we have been evaluating the drug for the past 2 years [10, 11].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kidd, J. G.: Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. exp. Med. 98, 565–581 (1953).PubMedCrossRefGoogle Scholar
  2. 2.
    Broome, J. D.: Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J. exp. Med. 118, 99–120 (1963).PubMedCrossRefGoogle Scholar
  3. 3.
    Mashburn, L. T., Wriston, J. C.: Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch. Biochem. Biophys. 105, 450–452 (1964).PubMedCrossRefGoogle Scholar
  4. 4.
    Old, L. J., Boyse, E. A., Campbell, H. A., Daria, G. M.: Leukaemia-inhibiting properties and L-asparaginase activity of sera from certain South American rodents. Nature (Lond.). 198, 801 (1963).CrossRefGoogle Scholar
  5. 5.
    Boyse, E. A., Old, L. J., Campbell, H. A., Mashburn, L. T.: Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase. J. exp. Med. 125, 17–31 (1967).PubMedCrossRefGoogle Scholar
  6. 6.
    De Barros, T., Filho, M. C., De Santana, C. F., Valenca, M., Da Silva, M. P., Guedes, J., De Carvalho, A. R. L.: Utilizacao de L-asparaginase em paciente humano portador de neoplasia maligna. An. Fac. Med. Recife. 25, 21–28 (1965).Google Scholar
  7. 7.
    Dolowy, W. C., Henson, D., Cornet, J., Sellin, H.: Toxic and antineoplastic effects of L-asparaginase. Cancer. 19, 1813–1819 (1966).PubMedCrossRefGoogle Scholar
  8. 8.
    Hill, J. M., Roberts, J., Loeb, E., Kahn, A., MacLellan, A., Hill, R. W.: L-asparaginase therapy for leukemia and other malignant neoplasms. J. Amer. med. Ass. 202, 882–888 (1967).CrossRefGoogle Scholar
  9. 9.
    Oettgen, H. F. et al.: Inhibition of leukemias in man by L-asparaginase. Cancer Res. 27, 2619–2631 (1967).PubMedGoogle Scholar
  10. 10.
    Burchenal, J. H., Oettgen, H. F.: The present clinical status of asparaginase. UICC (Union Internationale Contre le Cancer) Bulletin. 7, 5 (1969).Google Scholar
  11. 11.
    Karnofsky, D. A., Murphy, M. L., Oettgen, H. F.: Effects of L-asparaginase on leukemias and other neoplasms. International Society of Hematology, XIIth Congress (New York 1968), Abstracts of the Simultaneous Sessions, p. 7.Google Scholar
  12. 12.
    Schwartz, M. K., Lash, E. D., Oettgen, H. F., Tomao, F. A.: L-asparaginase activity in plasma and other biological fluids. Cancer Feb. 1970.Google Scholar
  13. 13.
    Haberland, G.: Personal communication.Google Scholar
  14. 14.
    Oettgen, H. F., Stephenson, P. A., Schwartz, M. K., Leeper, R. D., Tallal, L., Clarkson, B. D., Golbey, R. B., Krakoff, I. H., Karnofsky, D. A., Burchenal, J. H.: The toxicity of E. coli L-asparaginase in man. Cancer Feb. 1970.Google Scholar
  15. 15.
    Tallal, L., Tan, C., Oettgen, H., Wollner, N., McCarthy, M., Helson, L., Burchenal, J., Karnofsky, D., Murphy, M. L.: E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer Feb. 1970.Google Scholar
  16. 16.
    Clarkson, B., Krakoff, I., Burchenal, J., Karnofsky, D., Golbey, R., Oettgen, H., Dowling, M., Lipton, A.: Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer Feb. 1970.Google Scholar
  17. 17.
    Sobin, L. H., Kidd, J. G.: A metabolic difference between two lines of lymphoma 6C3HED cells in relation to asparagine. Proc. Soc. exp. Biol. Med. (N. Y.) 119, 325–327 (1965).CrossRefGoogle Scholar
  18. 18.
    Burchenal, J. H.: Success and failure in present chemotherapy and the implications of Asparaginase. Proceedings of the ACS-UICC Conference, “A Ccritical Evaluation of Cancer Chemotherapy” (Cherry Hill, N. J. 1969). Cancer Res. Dec. 1969.Google Scholar
  19. 19.
    Dollinger, M. R.: L-asparaginase in transplanted mouse leukemia. International Society of Hematology, XIIth Congress (New York 1968), Abstracts of the Simultaneous Sessions, p. 6.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1970

Authors and Affiliations

  • J. H. Burchenal
    • 1
  1. 1.Division of Applied Therapy, Sloan-Kettering Institute for Cancer Research and the Department of MedicineMemorial Hospital for Cancer and Allied DiseasesNew YorkUSA

Personalised recommendations